Skip to main content
Clinical Trials/IRCT20151126025252N1
IRCT20151126025252N1
Recruiting
Phase 3

Evaluation of the effectiveness of eight weeks of pulmonary rehabilitation on cardiopulmonary parameters and quality of life in patients with scleroderma with pulmonary involvement

Tehran University of Medical Sciences0 sites60 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Systemic Scleroderma.
Sponsor
Tehran University of Medical Sciences
Enrollment
60
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Patients with scleroderma according to the 2013 Eular criteria
  • FVC less than 80 percent or CT involvement more than 10 percent
  • No change in the medications taken by patients during the last 3 months
  • These patients should have the ability to do exercise in the hospital and at home

Exclusion Criteria

  • Overlap syndrome and MCTD
  • Inability to perform exercise
  • Contraindications to CPET include:1\) Unstable angina, 2\) Uncontrolled arrhythmia, 3\) Severe aortic stenosis,4\) Arterial oxygen with pulse oximetry less than 85% in room air,5\) Severe untreated arterial hypertension at rest (SBP200mmHg) (DBP120mmmHg ), 6\) Hypertrophic cardiomyopathy 7\) Significant orthopedic disorder, 8\) Mental disorder,9\) Clinical signs of heart failure (pulmonary or peripheral edema) or EF less than 50%, 10\) Severe valvular heart disease,11\) Pulmonary hypertension \>50 mmHg, 12\) Acute pulmonary embolism \- 13\) Sinus tachycardia more than 120,14\) Pericarditis, 15\) Acute myocarditis, 16\) Uncompensated heart failure, 17\) Acute systemic disease or fever, 18 ) Coronary disease in the last 4 weeks \-19\) Metabolic disease such as acute thyroiditis

Outcomes

Primary Outcomes

Not specified

Similar Trials